Utah firm Xlear Inc. responds to the Federal Trade Commission’s allegation that it doesn’t have substantiation to say its saline nasal spray formulation prevents and treats COVID-19 by arguing that it’s not making a health claim but referencing research showing efficacy for its product.
Contesting a complaint the Department of Justice filed for the FTC, Xlear becomes the latest consumer health products marketer to question the FTC’s insistence of randomized and controlled clinical trials
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?